Thermosensitive injectable hydrogel enhances the antitumor effect of embelin in mouse hepatocellular carcinoma

Journal of Pharmaceutical Sciences

Volumn 103, Issue 3, 2014, Pages 965-973

  Peng, Meiyu ^a   Xu, Shuxin ^b   Zhang, Yong ^c   Zhang, Lijuan ^a   Huang, Bingqing ^a   Fu, Shuyu ^a   Xue, Zhenyi ^a   Da, Yurong ^a   Dai, Yun ^d   Qiao, Liang ^e   Dong, Anjie ^b   Zhang, Rongxin ^a   Meng, Wenbo ^f  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b TIANJIN UNIVERSITY   (China)

^c Second People Hospital of Gansu Province   (China)

^d PEKING UNIVERSITY FIRST HOSPITAL   (China)

^e UNIVERSITY OF SYDNEY   (Australia)

^f LANZHOU UNIVERSITY   (China)

Author keywords

cancer; controlled release delivery; embelin; hydrogels; injectable; thermal gels

Indexed keywords

COPOLYMER; EMBELIN; POLY(EPSILON CAPROLACTONE CO 1,4,8 TRIOXA[4.6]SPIRO 9 UNDECANONE)POLY(ETHYLENE GLYCOL)POLY(EPSILON CAPROLACTONE CO 1,4,8 TRIOXA[4.6]SPIRO 9 UNDECANONE); UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BENZOQUINONE DERIVATIVE; DRUG IMPLANT; HYDROGEL; MACROGOL DERIVATIVE; POLY(EPSILON-CAPROLACTONE-CO-1,4,8-TRIOXA(4.6)SPIRO-9-UNDECANONE)-POLY(ETHYLENE GLYCOL)-POLY(EPSILON-CAPROLACTONE-CO-1,4,8-TRIOXA(4.6)SPIRO-9-UNDECANONE); POLYESTER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; AQUEOUS SOLUTION; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG MEGADOSE; DRUG RELEASE; ENVIRONMENTAL TEMPERATURE; HEAT SENSITIVITY; HYDROGEL; IN VITRO STUDY; IN VIVO STUDY; INJECTION SITE; LIVER CELL CARCINOMA; LOCAL THERAPY; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; ANIMAL; APOPTOSIS; BAGG ALBINO MOUSE; BODY TEMPERATURE; CANCER TRANSPLANTATION; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECTS; DRUG IMPLANT; LIVER; LIVER NEOPLASMS; PATHOLOGY; PHASE TRANSITION; RANDOMIZATION; SOLUBILITY; TOXICITY; TOXICITY TESTING; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BENZOQUINONES; BODY TEMPERATURE; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG IMPLANTS; HYDROGELS; LIVER; LIVER NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; PHASE TRANSITION; POLYESTERS; POLYETHYLENE GLYCOLS; RANDOM ALLOCATION; SOLUBILITY; TOXICITY TESTS; TUMOR BURDEN;

EID: 84894501348     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23885     Document Type: Article

References (32)

1. Yang L, Parkin DM, Ferlay J, Li L, Chen Y,. 2005. Estimates of cancer incidence in China for 2000 and projections for 2005. Cancer Epidemiol Biomarkers Prev 14 (1): 243-250.
2. Parkin DM, Bray F, Ferlay J, Pisani P,. 2005. Global cancer statistics, 2002. CA Cancer J Clin 55 (2): 74-108.
3. Bruix J, Sherman M,. 2005. Management of hepatocellular carcinoma. Hepatology 42 (5): 1208-1236.
4. Lord R, Suddle A, Ross PJ,. 2011. Emerging strategies in the treatment of advanced hepatocellular carcinoma: The role of targeted therapies. Int J Clin Pract 65 (2): 182-188.
5. Pelletier SJ, Fu S, Thyagarajan V, Romero-Marrero C, Batheja MJ, Punch JD, Magee JC, Lok AS, Fontana RJ, Marrero JA,. 2009. An intention-to-treat analysis of liver transplantation for hepatocellular carcinoma using organ procurement transplant network data. Liver Transpl 15 (8): 859-868.
6. Aird KM, Ghanayem RB, Peplinski S, Lyerly HK, Devi GR,. 2010. X-linked inhibitor of apoptosis protein inhibits apoptosis in inflammatory breast cancer cells with acquired resistance to an ErbB1/2 tyrosine kinase inhibitor. Mol Cancer Ther 9 (5): 1432-1442.
7. Allensworth JL, Aird KM, Aldrich AJ, Batinic-Haberle I, Devi GR,. 2012. XIAP inhibition and generation of reactive oxygen species enhances TRAIL sensitivity in inflammatory breast cancer cells. Mol Cancer Ther 11 (7): 1518-1527.
8. Kalyan Kumar G, Dhamotharan R, Kulkarni NM, Mahat MY, Gunasekaran J, Ashfaque M,. 2011. Embelin reduces cutaneous TNF-alpha level and ameliorates skin edema in acute and chronic model of skin inflammation in mice. Eur J Pharmacol 662 (1-3): 63-69.
9. Joshi R, Kamat JP, Mukherjee T,. 2007. Free radical scavenging reactions and antioxidant activity of embelin: Biochemical and pulse radiolytic studies. Chem Biol Interact 167 (2): 125-134.
10. Singh D, Singh R, Singh P, Gupta RS,. 2009. Effects of embelin on lipid peroxidation and free radical scavenging activity against liver damage in rats. Basic Clin Pharmacol Toxicol 105 (4): 243-248.
11. Poojari R, Gupta S, Maru G, Khade B, Bhagwat S,. 2010. Chemopreventive and hepatoprotective effects of embelin on N-nitrosodiethylamine and carbon tetrachloride induced preneoplasia and toxicity in rat liver. Asian Pac J Cancer Prev 11 (4): 1015-1020.
12. Che Y, Ye F, Xu R, Qing H, Wang X, Yin F, Cui M, Burstein D, Jiang B, Zhang DY,. 2012. Co-expression of XIAP and cyclin D1 complex correlates with a poor prognosis in patients with hepatocellular carcinoma. Am J Pathol 180 (5): 1798-1807.
13. Huang Y, Lu J, Gao X, Li J, Zhao W, Sun M, Stolz DB, Venkataramanan R, Rohan LC, Li S,. 2012. PEG-derivatized embelin as a dual functional carrier for the delivery of paclitaxel. Bioconjug Chem 23 (7): 1443-1451.
14. Jeong B, Bae YH, Kim SW,. 2000. Drug release from biodegradable injectable thermosensitive hydrogel of PEG-PLGA-PEG triblock copolymers. J Control Release 63 (1-2): 155-163.
15. Kissel T, Li Y, Unger F,. 2002. ABA-triblock copolymers from biodegradable polyester A-blocks and hydrophilic poly(ethylene oxide) B-blocks as a candidate for in situ forming hydrogel delivery systems for proteins. Adv Drug Deliv Rev 54 (1): 99-134.
16. Jeong B, Bae YH, Lee DS, Kim SW,. 1997. Biodegradable block copolymers as injectable drug-delivery systems. Nature 388 (6645): 860-862.
17. DuVall GA, Tarabar D, Seidel RH, Elstad NL, Fowers KD,. 2009. Phase 2: A dose-escalation study of OncoGel (ReGel/paclitaxel), a controlled-release formulation of paclitaxel, as adjunctive local therapy to external-beam radiation in patients with inoperable esophageal cancer. Anticancer Drugs 20 (2): 89-95.
18. Vukelja SJ, Anthony SP, Arseneau JC, Berman BS, Cunningham CC, Nemunaitis JJ, Samlowski WE, Fowers KD,. 2007. Phase 1 study of escalating-dose OncoGel (ReGel/paclitaxel) depot injection, a controlled-release formulation of paclitaxel, for local management of superficial solid tumor lesions. Anticancer Drugs 18 (3): 283-289.
19. Hwang MJ, Suh JM, Bae YH, Kim SW, Jeong B,. 2005. Caprolactonic poloxamer analog: PEG-PCL-PEG. Biomacromolecules 6 (2): 885-890.
20. Ma G, Miao B, Song C,. 2010. Thermosensitive PCL-PEG-PCL hydrogels: Synthesis, characterization, and delivery of proteins. J Appl Polym Sci 116 (4): 1985-1993.
21. Wang W, Deng L, Liu S, Li X, Zhao X, Hu R, Zhang J, Han H, Dong A,. 2012. Adjustable degradation and drug release of a thermosensitive hydrogel based on a pendant cyclic ether modified poly(epsilon-caprolactone) and poly(ethylene glycol)co-polymer. Acta Biomater 8 (11): 3963-3973.
22. Wang W, Deng L, Huang P, Xu S, Li X, Lv N, Wang L, Hu R, Zhang J, Dong A,. 2014. Toxicity and in vivo biological effect of the nanoparticular self-supported hydrogel of a thermosensitive copolymer for noninvasive drug delivery. J Biomed Mater Res A 102 (1): 17-29.
23. Wang W, Deng L, Xu S, Zhao X, Lv N, Zhang G, Gu N, Hu R, Zhang J, Liu J, Dong A,. 2013. A reconstituted "two into one" thermosensitive hydrogel system assembled by drug-loaded amphiphilic copolymer nanoparticles for the local delivery of paclitaxel. J Mater Chem B 1 (4): 552-563.
24. Min KH, Lee HJ, Kim K, Kwon IC, Jeong SY, Lee SC,. 2012. The tumor accumulation and therapeutic efficacy of doxorubicin carried in calcium phosphate-reinforced polymer nanoparticles. Biomaterials 33 (23): 5788-5797.
25. Ashley CE, Carnes EC, Phillips GK, Durfee PN, Buley MD, Lino CA, Padilla DP, Phillips B, Carter MB, Willman CL, Brinker CJ, Caldeira Jdo C, Chackerian B, Wharton W, Peabody DS,. 2011. Cell-specific delivery of diverse cargos by bacteriophage MS2 virus-like particles. ACS Nano 5 (7): 5729-5745.
26. Zhang X, Guo S, Fan R, Yu M, Li F, Zhu C, Gan Y,. 2012. Dual-functional liposome for tumor targeting and overcoming multidrug resistance in hepatocellular carcinoma cells. Biomaterials 33 (29): 7103-7114.
27. Dai LC, Yao X, Wang X, Niu SQ, Zhou LF, Fu FF, Yang SX, Ping JL,. 2009. In vitro and in vivo suppression of hepatocellular carcinoma growth by midkine-antisense oligonucleotide-loaded nanoparticles. World J Gastroenterol 15 (16): 1966-1972.
28. Chaturvedi K, Ganguly K, Nadagouda MN, Aminabhavi TM,. 2013. Polymeric hydrogels for oral insulin delivery. J Control Release 165 (2): 129-138.
29. Babu VR, Patel P, Mundargi RC, Rangaswamy V, Aminabhavi TM,. 2008. Developments in polymeric devices for oral insulin delivery. Expert Opin Drug Deliv 5 (4): 403-415.
30. Mundargi RC, Rangaswamy V, Aminabhavi TM,. 2011. Poly(N-vinylcaprolactam- co-methacrylic acid) hydrogel microparticles for oral insulin delivery. J Microencapsul 28 (5): 384-394.
31. Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE,. 2001. Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release 70 (1-2): 1-20.
32. Yu L, Ding J,. 2008. Injectable hydrogels as unique biomedical materials. Chem Soc Rev 37 (8): 1473-1481.